Brief: Biophytis, Seqens Sign A Partnership To Produce Sarconeos Active Compound
18/07/2023 06:04
July 18 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS AND SEQENS SIGN A PARTNERSHIP TO PRODUCE
SARCONEOS
(BIO101) ACTIVE COMPOUND
* SEQENS WILL PRODUCE THE ACTIVE INGREDIENT IN SARCONEOS
(BIO101)
IN FRANCE AT ITS VILLENEUVE LA GARENNE PLANT, NEAR PARIS
Source text for Eikon: ID:nEQ4cPrMJa
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon